Investor Presentaiton
Laurus Bio - Bio business
Demand upbeat
Revenue Growth
39
[Cr]
Y-o-Y 44%
Q-o-Q22%
Comments
■
■
Reported strong growth for Q2 and H1 at +44% and +56% YoY, led by
traction in CDMO services along with customer addition
Acquired 13.2%* additional stake of Laurus Bio - Reflects confidence
on growing application of enzyme technology platform both internally
and externally, signaling great potential
■ R2 capacities being optimized with large-scale CDMO partners and
further expect downstream capacity going on-line from Dec'23
■
Expanding bio-catalysis platform application in small molecule
commercial DS projects and explore new opportunities in Semi-
synthetic biology
Large scale fermentation capacity R3 design phase completed. Project
to be executed in phased manner
50
50
46
46
27
22
الاس
2Q
FY23
3Q
FY23
4Q
1Q
FY23
FY24
2Q
FY24
* On 11 Sep 2023 Laurus Lab acquired additional stake in Laurus Bio from one of the Promoters and non-
executive director and his family members and also with few employees/ex-employee shareholders. Post
acquisition Laurus will hold 87.58% on fully diluted basis in Laurus Bio
23
23
Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023
LAURUS Labs
Knowledge. Innovation. ExcellenceView entire presentation